Cashu Logo
HomeWatchlistNewsSignalsPicks
DJI
-0.10%
SPX
+0.35%
IXIC
+0.72%
FTSE
+0.31%
N225
-0.88%
AXJO
-1.82%
Cashu Logo
Log In
HomeWatchlistNewsSignalsPicks
Stocks
0.00 (0.00%)
0.000
USD
At close at --,----
Cashu Logo Alt
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

  • About Us
  • Careers
  • Blog
  • News

Help & Support

  • Help Center
  • Contact Us
  • Pro Support

Legal

  • Privacy Policy
  • Terms of Use
InstagramYouTube

© 2024 Cashu PTY LTD.

Join our newsletter to keep up to date with us!

Overview

Loading chart...

Key Stats

Market Cap
14.05B
Dividend Yield
0.00%
P/E Ratio
40.33
EPS
3.38
Revenue
2.36B
Avg. Volume
620.14K

Recently from Cashu

publisher logo
Cashu

Neurocrine Biosciences Engages Investors at Upcoming Healthcare Conferences in September 2025

5 days ago
publisher logo
Cashu

Neurocrine Biosciences Highlights Neuroscience Commitment at September 2025 Investor Conferences

6 days ago
publisher logo
Cashu

Neurocrine Biosciences (NBIX) Prepares for Key Investor Conferences in September 2025

8 days ago

About

What does NBIX do?
Neurocrine Biosciences, based in San Diego, develops pharmaceuticals for neurological disorders and employs 1,448 people. Its FDA-approved products include INGREZZA and Orilissa, with a strong clinical development pipeline.
Sector
💻 Health Care
IPO
CEO
Employees
1,800
Headquarters
California, USA
Website
http://www.neurocrine.com
Stocks
Health Care
nbix
Neurocrine Biosciences
NASDAQ: NBIX
+2.23 (0.00%)
141.83
USD
At close at Sep 03, 13:26 UTC
Summary
News
Signals
Benchmarks
Financials